Special Issues

Special Issue Title: Maternal Fetal Medicine

· Print Special Issue Flyer

· Deadline for manuscript submissions: 30 December 2021

Special Issue Editor

Guest Editor

Dr. Paolo Ivo Cavoretto

Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Vita-Salute University, Milan 20132, Italy 

Website1 | Website2 | E-Mail

Interests: Fetal Medicine and Surgery; Obstetrics; Pregnancy complications; Ultrasound; Doppler; MRI; Screening in pregnancy; Congenital Malformations; Congenital Heart Defects; Open Spina Bifida; Fetal Growth; Preterm delivery; Preeclampsia; Pregnancy after Medically Assisted Reproduction

Special Issue Information

Dear Colleagues,

The practice of Maternal Fetal Medicine deals with a dyad of patients and requires a broad range of specific expertise in order to recompose such dichotomy. Mother and fetus, through their placental connection, present such deep interrelationships that abnormalities on one side have the potential to determine clinically relevant consequences on the other. Gestational or pre-gestational anomalies in the mother may determine risk of dysfunctional placentation, abnormal fetal growth or prematurity, up to perinatal demise. On the other hand, fetal abnormalities may affect maternal well-being and organ function. Extensive evaluation of the two patients in object requires multidisciplinary assessment with expert in maternal or fetal medicine sharing their knowledge for the benefits of mothers and their unborn babies.

The aim of this Special Issue of Clinical and Experimental Obstetrics & Gynecology is to explore the interrelationship of this two components welcoming both recent advances and developments in the field of fetal and maternal medicine, including early diagnosis of fetal abnormalities, screening and diagnosis for chromosomal defects and genetic syndromes, intrauterine fetal surgery, prediction and prevention of preeclampsia, preterm birth, stillbirth, prediction and management of abnormal fetal growth, obstetric problems of multiple pregnancies, and medically assisted reproduction, fetal and maternal diseases in pregnancies (both gestational and pre-gestational). Submissions of original unpublished studies are welcome, including observational and interventional studies as well as RCTs and reviews, with an emphasis on relevant clinical questions and quantitative syntheses (meta-analyses) of pooled data. Authors are welcome to contact the Editorial Team in advance if they require any assistance for the preparation of their manuscript.

Dr. Paolo Cavoretto

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ceog.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Clinical and Experimental Obstetrics & Gynecology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.


Prenatal screening and diagnosis; Fetal medicine and surgery; Obstetric ultrasound; Fetal abnormalities; Chromosomal defects and genetic syndromes; Pre-gestational/chronic maternal diseases in pregnancy; Gestational maternal diseases; Pregnancy complications; Pre-eclampsia; Fetal growth restriction; Preterm delivery; Stillbirth

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review
Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina
Clinical and Experimental Obstetrics & Gynecology    2021, 48 (4): 812-819.   DOI: 10.31083/j.ceog4804130
Abstract248)   HTML21)    PDF(pc) (413KB)(70)       Save

Background: Preeclampsia (PE) is a multisystem disease of pregnancy representing a major cause of maternal and perinatal morbidity and mortality. Early identification of pregnancies at risk of developing PE is crucial for implementing preventive strategies. The effectiveness of PE screening in the first trimester is widely recognized and endorsed by several guidelines, but unfortunately real-world implementation of this practice within local settings remains difficult. Methods: We performed a systematic review of the literature to understand the critical issues hampering the implementation of PE screening procedures in Italy. All studies on first trimester PE screening in the Italian population were eligible for inclusion. Key-concepts relevant for implementation of PE screening in Italy were extracted and analysed qualitatively. Results: Nine articles were selected and included. Lack of evidence concerning the topic of PE screening in Italy was shown. Major critical issues found encompassed health-care personnel education, training of sonographers, economic coverage for biochemical markers and adjustment of algorithms based on population characteristics. Conclusions: Identification and adaptation of specific protocols to local settings and population characteristics is critical for successful implementation of early PE screening in Italy. This process has the potential to improve pregnancy outcomes and to save valuable health-care resources, particularly scarce in the COVID-19 era. There is an urgent need for research studies on specific local populations focussing on subtle details capable of maximizing PE screening uptake. This action will likely potentiate PE screening implementation reducing the burden and the cost of perinatal and maternal complications.
Related Articles | Metrics
Comparison of application of Fenton, Intergrowth-21st and WHO growth charts in a population of Polish newborns
Dominik Jakubowski, Daria Salloum, Marek Maciejewski, Magdalena Bednarek-Jędrzejek, Anna Kajdy, Aneta Cymbaluk-Płoska, Ewa Kwiatkowska, Andrzej Torbé, Sebastian Kwiatkowski
Clinical and Experimental Obstetrics & Gynecology    2021, 48 (4): 949-954.   DOI: 10.31083/j.ceog4804150
Abstract114)   HTML4)    PDF(pc) (113KB)(72)       Save

Background: Growth charts are the primary tools for evaluating neonatal birth weight and length. They help and qualify the neonates as Appropriate for Gestational Age (AGA), Small for Gestational Age (SGA), or Large for Gestational Age (LGA). The most commonly used neonatal charts include Intergrowth-21st, WHO, and Fenton. The aim of the study was to compare the tools used for assessing neonatal birth weight and the incidence of SGA and LGA using the different charts. Methods: Data on 8608 births in the Clinical Department of Obstetrics and Gynecology were compared. We divided the patient population into five gestational age groups. The 10th and 90th percentiles were calculated. The percentage of cases meeting the SGA and LGA criteria was determined. Results: Statistically significant differences between growth charts were identified for each of the groups. The 10th percentile for the study population corresponded to 2970 g for females and 3060 g for males born in the 40th week of gestation. The 90th percentile values were 4030 g and 4120 g. Our analysis showed a statistically significant difference in detection of LGA or SGA between three growth charts and our data both in male (χ2(3) = 157.192, p < 0.001, Kramer's V = 0.444) and female newborns (χ2(3) = 162.660, p < 0.001, Kramer's V = 0.464). Discussion: Our results confirm that differences exist between growth charts. There is a need for harmonizing growth assessment standards. It is recommended that a growth chart should be developed for the Polish population, which would improve the diagnosis of SGA and LGA.
Related Articles | Metrics

Current Issue

  • Volume 48, Issue 5